National Institute of Allergy andInfectious Diseases (NIAID) http://www.niaid.nih.gov
FOR IMMEDIATE RELEASE
April 29, 1997
Many countries have joined the desperate cry for an AIDS vaccine. What is the current state of research? NIAID invites you to find out at the largest national meeting focused exclusively on AIDS vaccine research.
This year, the emphasis will be on immune responses to and protection against HIV. Topics include pathogenic events in acute infection and predictors of disease progression; HIV transmission studies; mucosal immunity; DNA and other novel vaccine designs; studies in primates; and Phase I human trials.
Midday briefings for science writers will highlight important topics of discussion at the meeting (see attached schedule). NIAID staff also will present a special introductory level overview of vaccine immunology and HIV virology and question-and-answer opportunity Monday morning. All scientific sessions of the meeting are open to registered members of the press.
For more information, call Laurie Doepel in NIAID’s Office of Communications and Public Liaison at 301-402-1663.
When: Sunday through Wednesday, May 4-7, 1997
Where: The Natcher Conference Center45 Center DriveNational Institutes of Health (NIH)Bethesda, Md.(As parking is very limited, we encourage you to take the Metro Red Lineto the Medical Center stop, which is on the NIH campus)
Sponsors: National Institute of Allergy and Infectious Diseases, NIHCenters for Disease Control and PreventionDepartment of DefenseFogarty International Center, NIHFood and Drug AdministrationOffice of AIDS Research, NIH
ADVANCES IN AIDS PATHOGENESIS AND PRECLINICAL VACCINE DEVELOPMENT May 4-7, 1997Natcher Conference Center, National Institutes of Health (NIH)
MEETING SPONSORS: National Institute of Allergy and Infectious Diseases (NIAID)Office of AIDS Research, NIH
Schedule, May 5-7
SPECIAL PRESENTATION Monday, May 5, 10:30-11:15 a.m. Mary Allen, Division of AIDS (DAIDS), NIAID Introduction to vaccine immunology and HIV virology. (Room C1)
All other briefings will be held from 12:30 to 1:30 p.m., Monday through Wednesday, in Room C1 of the Natcher Conference Center. Each speaker will make a brief presentation followed by a question-and-answer session.
Dr. Kent Weinhold, Duke University Medical Center, Durham, N.C. AIDS Vaccine Evaluation Group vaccine trials: immunology lessons.
Dr. Connie Celum, University of Washington, Seattle, Washington, and Dr. Haynes Sheppard, California Department of Health, Berkeley, Calif. Study of acute infection in HIV-infected participants in the HIVNET study:implications for HIV vaccine development.
Dr. Larry Arthur, National Cancer Institute, NIH DNA vaccines and other novel HIV vaccine designs.
Dr. Patricia Fast, DAIDS, NIAID, NIH Overall NIAID HIV vaccine research strategy and vaccines in the pipeline.
Dr. Opendra Narayan, University of Kansas Medical Center, Kansas City, Mo. Development and studies of a pathogenic SHIV in macaques.
Dr. Carl Dieffenbach, DAIDS, NIAID, NIH HIV pathogenesis research: lessons for HIV vaccine design.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated April 29, 1997